Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of “Moderate Buy” by Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has received an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $41.10.

KYMR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Piper Sandler boosted their price target on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Truist Financial boosted their price target on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Oppenheimer dropped their price target on shares of Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating for the company in a research note on Friday, May 3rd. Finally, Wolfe Research began coverage on shares of Kymera Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company.

Insider Activity

In other news, CFO Bruce N. Jacobs sold 3,934 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $41.86, for a total value of $164,677.24. Following the completion of the sale, the chief financial officer now directly owns 142,351 shares of the company’s stock, valued at $5,958,812.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Bruce Booth sold 71,764 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the completion of the transaction, the director now directly owns 806,697 shares of the company’s stock, valued at $32,638,960.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Bruce N. Jacobs sold 3,934 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $41.86, for a total transaction of $164,677.24. Following the transaction, the chief financial officer now directly owns 142,351 shares of the company’s stock, valued at $5,958,812.86. The disclosure for this sale can be found here. Over the last three months, insiders sold 423,529 shares of company stock valued at $17,815,113. Insiders own 15.82% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in KYMR. Quest Partners LLC acquired a new position in Kymera Therapeutics during the fourth quarter worth about $78,000. Comerica Bank grew its position in Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after buying an additional 400 shares during the period. Ameritas Investment Partners Inc. grew its position in Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after buying an additional 295 shares during the period. Virtu Financial LLC acquired a new position in Kymera Therapeutics during the first quarter worth about $207,000. Finally, Allspring Global Investments Holdings LLC grew its position in Kymera Therapeutics by 33.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 5,183 shares of the company’s stock worth $72,000 after buying an additional 1,310 shares during the period.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $35.70 on Friday. The stock has a market capitalization of $2.19 billion, a P/E ratio of -14.22 and a beta of 2.31. The company has a 50 day moving average price of $36.99 and a 200 day moving average price of $31.71. Kymera Therapeutics has a fifty-two week low of $9.60 and a fifty-two week high of $45.31.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. The firm had revenue of $10.30 million during the quarter, compared to analysts’ expectations of $14.24 million. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.70) EPS. Research analysts forecast that Kymera Therapeutics will post -2.86 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.